Human longitudinal studies of health and aging available nowadays have collected repeated measurements of numerous biomarkers, along with follow-up information on mortality, onset of diseases and other health and aging-related variables. This provides opportunity for analyses of dynamics of biomarkers in relation to mortality and other time-to-event outcomes. Such analyses can use different analytic approaches, based on individual biomarkers, as well as on cumulative measures combining the information on multiple biomarkers, see recent review in ([@CIT0001]). Recently suggested novel implementation of the statistical distance measure (denoted as D~M~) allows for estimating the level of "physiological dysregulation" (PD) in aging individuals based on the information about multiple biomarker profiles ([@CIT0002],[@CIT0003]). D~M~ reduces the high-dimensional biomarker space into a single measure of PD that summarizes the information about biomarker deviations from a specified "physiological norm" or a baseline state. D~M~ is a continuous measure, and therefore, it conceptualizes PD differently than, for example, allostatic load which can also be considered as an index of PD ([@CIT0004]) and which counts "high-risk" values of biomarkers based on either empirical or clinical practice thresholds. Available longitudinal data can be used to study the relationships between PD and longevity and other health and aging-related outcomes, including those representing declines in physical resilience and robustness, which are key characteristics of biological aging ([@CIT0005]).

*Physical (or biological) resilience* could be defined as one's ability to bounce back after a deviation from a normal or baseline physiological state, or quickly and completely recover after stress, damage or an adverse health event ([@CIT0005]). Physical resilience declines during aging, meaning that elderly individuals are able to survive and recover after an adverse health event less quickly and completely than they were able to do at younger ages. The decline in resilience is a universal feature of aging, which contributes to an increase in vulnerability to death with age even in apparently healthy individuals, and to longevity limits (a.k.a. maximum longevity). Phenotypes characterizing resilience can be studied at different levels of biological organization (cell, tissue, organ, system, body), as well as may represent more than one such level ([@CIT0006],[@CIT0008],[@CIT0009]). For instance, the speed and quality of DNA repair would characterize resilience at the cellular level; the ability to restore blood pressure back to normal after a deviation caused by cold stress, or the ability to quickly heal a hip fracture, would represent resilience at the tissue or organ levels; and the ability to survive following an adverse health event would characterize resilience at the whole body level. Given the integrated nature of body functioning, the latter type of resilience will be the focus of this article. Indeed, a localized damage (such as hip fracture) may affect not only the resilience of respective tissue but sometimes lead to weakening of the whole body, so that even successful healing of the specific body part (hip) may not necessarily mean a full recovery at the whole body level. It is well known that elderly people with fractures continue to have a significant mortality excess many years after the injury ([@CIT0010],[@CIT0011]), suggesting additional factors (besides the fracture per se) that may negatively affect resilience. We thus decided to investigate resilience at an aggregated level, as the ability to survive following the onset of unhealthy life, and will use this definition as a proxy for the whole body physical resilience in this study, being fully aware of limitations of this (and any other) definition of resilience.

*Physical robustness* could be defined as the ability to resist the deviation from the baseline or the "normal" physiological state and shield oneself from an adverse health event by preventing it from happening in first place, thus avoiding its destructive consequences whatsoever ([@CIT0005]). As with resilience, robustness can be studied at different levels of biological organization (cell, tissue, organ, system, body). For instance, the ability of skin cells to avoid UV-induced DNA damage may represent robustness at the cell level; the ability to prevent a large deviation of blood pressure from its baseline after a cold stress would characterize robustness at the tissue or organ level; and the ability to protect oneself from a disease occurrence would characterize robustness at the whole body level. In this article, we will focus on an aggregated indicator of the whole body robustness, "onset of unhealthy life," which refers to the onset of any disease belonging to this group: cancer, cardivascular diseases (CVDs), diabetes. The whole body robustness declines during aging; it, however, may improve in specific health domains. For instance, vulnerability to particular infectious disease (eg, flu) may diminish following the immunization against this disease, so the robustness in relation to such disease may become better later in life. Some internal exposures may also change during aging in a way improving the robustness in relation to particular health disorder. For example, the drop in internal exposure to estrogens during menopause may favor the decline in risk of endometrial cancer later in life, which means an improved robustness in relation to this cancer ([@CIT0012],[@CIT0013]).

Aging changes in robustness and resilience are obviously mutually connected and may affect each other, eg, through the use of the same body resource (reserve). For instance, getting sick too often would be an indicator of low robustness. In order to recover from the illness, the body needs to use its resources, such as stem and immune cells reserves. When an appropriate portion of the body reserves is spent on the recovery process (resilience) and restoration of health (robustness), this partial loss of the reserves may diminish the organism's ability to respond to and recover from the next health problem, which in the long-term may contribute to the decline in resilience limiting longevity of this organism.

Analysis of the dynamics of D~M~ in relation to the proxies for physical robustness and resilience, such as disease onset and survival after disease, respectively, can be performed using appropriate analytical techniques such as the Cox regression model with time-dependent covariates or a recently developed biodemographic model of aging known as the stochastic process model (SPM) ([@CIT0014]). The latter approach can provide additional insights relevant in research on aging as the model conceptualizes several aging-related mechanisms in its structure which allow evaluation of "hidden" characteristics of aging-related changes not otherwise available in the data. D~M~ has recently been implemented in the framework of SPM ([@CIT0015]). Application of D~M~ in SPM allows for investigation of relationships between PD and other aging-related characteristics, not directly observable in data (such as decline in stress resistance and adaptive capacity), in the context of proxies for resilience, robustness, and total mortality.

The goal of this study was to measure PD in aging individuals, based on D~M~, and investigate relationships between the level of PD and onset of unhealthy life (proxy for robustness), survival following the onset of unhealthy life (proxy for resilience), and total mortality, using data on dynamics of biomarkers available from two large longitudinal human studies: Framingham Heart Study (original cohort) and Cardiovascular Health Study (CHS), and applying two approaches: the Cox proportional hazards model, and the SPM.

Data and Methods {#s1}
================

Data {#s2}
----

In this study, we used the FRAMCOHORT (Framingham Heart Study Cohort) Research Materials (version 2017b) and the CHS Research Materials (version 2015a) provided by the National Heart, Lung, and Blood Institute's (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) resource (<https://biolincc.nhlbi.nih.gov/home/>). Details are provided in [Supplementary Material](#sup1){ref-type="supplementary-material"}.

Proxies for Robustness and Resilience {#s3}
-------------------------------------

As mentioned, physical robustness and resilience can be described by various biomarkers representing different levels of biological organization (cell, tissue, organ, system, body; see Introduction for detail). In this study, we focus on the robustness and resilience at the whole body level, and use "onset of unhealthy life" as a proxy indicator of the robustness, and "survival following the onset of unhealthy life" as the proxy indicator of the resilience.

We define the "age at onset of unhealthy life," as the age of first occurrence of any disease from this group of major complex diseases: cancer, CVD (including coronary heart disease, CHD, stroke or congestive heart failure, CHF), and type 2 diabetes. If the individual did not contract any of these diseases during the observation period, then she or he was considered censored at the age of the last follow-up or death. Individuals who have cancer or CVD before the first exam, or diabetes at the first exam, were excluded from the analyses. The analyses of survival after disease onset were limited to the individuals who acquired any of respective diseases during the follow-up period.

In addition, we analyzed data on all-cause mortality as the ultimate outcome. Note that in ref. ([@CIT0015]) we reported results of analyses of D~M~ and mortality in the Framingham Heart Study original cohort using SPM. These results are different from those reported in this paper because the present study uses more recent data with longer follow up and more examinations (physiological measurements).

[Table 1](#T1){ref-type="table"} shows sample characteristics of FRAMCOHORT and CHS. The numbers related to the entire follow-up period correspond to the analyses using the Cox regression models and the continuous-time SPM. The numbers during the specific period since the last observation of D~M~ (2 years for FRAMCOHORT and 1 year for CHS) correspond to analyses of the discrete-time SPM.

###### 

Characteristics of Framingham Heart Study Original Cohort (FRAMCOHORT) and Cardiovascular Heart Study (CHS) Used in the Analyses

  Characteristics                                                                                   FRAMCOHORT   CHS                               
  ------------------------------------------------------------------------------------------------- ------------ -------- -------- ------- ------- --------
  Number of individuals                                                                             2,785        2,294    5,079    3,329   2,466   5,795
  Number of deaths during entire follow-up period                                                   2,653        2,252    4,905    2,469   2,112   4,581
  Number of individuals with onset of "unhealthy life" during entire follow-up period               2,015        1,841    3,856    2,192   1,756   3,948
  Number of individuals with onset of "unhealthy life" who died during entire follow-up period      1,535        1,467    3,002    1,178   1,182   2,360
  Number of deaths since last observation of D~M~^a^                                                1,335        1,286    2,621    749     863     1,612
  Number of individuals with onset of "unhealthy life" since last observation of D~M~^a^            1,583        1,524    3,107    1,313   1,242   2,555
  Number of individuals with onset of "unhealthy life" who died since last observation of D~M~^a^   982          974      1956     495     579     1,074
  Number of observations of D~M~ in the total sample                                                35,142       26,586   61,728   9,986   7,404   17,390
  Number of individuals in the "reference population"                                               1,103        908      2,011    1,330   854     2,184
  Number of observations of D~M~ in the "reference population"                                      1,039        858      1,897    1,319   847     2,166

*Note*: ^a^FRAMCOHORT numbers reflect 2 y after last observation of the measure of physiological dysregulation (D~M~); CHS numbers reflect 1 y after last observation of D~M~.

Mahalanobis Distance (D~M~) as Measure of PD {#s4}
--------------------------------------------

We used D~M~ (the Mahalanobis distance, see refs. ([@CIT0016],[@CIT0017])) to evaluate deviations of multiple biomarkers from a baseline physiological state and reduce the high-dimensional biomarker space into a single estimate representing the level of PD in the aging body. Details about the rationale of the use of the D~M~ as a measure of PD and its characteristics are given in works by Cohen and colleagues ([@CIT0002],[@CIT0003],[@CIT0018],[@CIT0019]). In this study, we are interested in effects of longitudinal dynamics of D~M~. Therefore, for our analyses, we selected physiological variables measured at a sufficient number of exams in both datasets and whose dynamic characteristics have been shown to be related to the outcomes of our interest (mortality risk and risk of onset of "unhealthy life") in our earlier applications of SPM to the Framingham data, see eg, ([@CIT0020]). Eight physiological variables were used in calculations of D~M~: blood glucose (BG), body mass index (BMI), total cholesterol (TC), diastolic blood pressure (DBP), hematocrit (HC), pulse pressure (PP), systolic blood pressure (SBP), and ventricular rate (VR). As there is a linear relationship between DBP, SBP, and PP, three different D~M~ variants were constructed which contain two out of these three: D~M1~: BG, BMI, TC, DBP, HC, SBP, VR; D~M2~: BG, BMI, TC, DBP, HC, PP, VR; and D~M3~: BG, BMI, TC, HC, PP, SBP, VR. We repeated all computations using these three D~M~ variants. The results were similar in all three variants; thus, we keep those with D~M1~ in the main text and show D~M2~ and D~M3~ in [Supplementary Material](#sup1){ref-type="supplementary-material"}. [Supplementary Material](#sup1){ref-type="supplementary-material"} also contains more details about calculations of D~M~.

Statistical Analysis {#s5}
--------------------

We ran the Cox proportional hazards model with D~M~ as the time-dependent covariate. Sex (coded as 0 -- females, 1 -- males) was used as an additional covariate in FRAMCOHORT. In CHS, we also adjusted for race (coded as 0 -- whites; 1 -- all other). Age at the first exam was used as the left truncation variable in analyses of mortality and robustness. Time since onset of "unhealthy life" was used as the time variable in the model for resilience and age at onset of "unhealthy life" was included as a covariate in such analyses. Analyses with the Cox model were done using SAS 9.4.

We also applied the SPM ([@CIT0014]) to investigate the dynamic relationships between D~M~ and other aging-related characteristics, not directly observable in data (such as declines in stress resistance and adaptive capacity), in the context of proxies for resilience, robustness and total mortality. We used specification of SPM as in ([@CIT0015]). Analyses with SPM were performed using the discrete-time specification of the model ([@CIT0025]) in MATLAB R2017b and using the continuous-time specification in a recently developed R-package *stpm* (<https://cran.r-project.org/web/packages/stpm/index.html>) ([@CIT0026]) ([Supplementary Material](#sup1){ref-type="supplementary-material"}).

Results and Discussion {#s6}
======================

The average D~M~ is 3.19 (*SD*: 1.15) in FRAMCOHORT and 2.6 (0.87) in CHS. Note that the age range in reference populations is different in the two studies hence D~M~ variables are on a different scale. This is also reflected in the dynamics of these variables with age in the two studies. On average, D~M~ changes 0.048 per year in FRAMCOHORT and 0.029 in CHS.

To check whether D~M~ adds anything in terms of predictive accuracy compared to calendar age, we computed areas under the receiver operating characteristic curves (AUC) for the models with and without D~M~ (using the last observed value before respective event in logistic regression adjusted also for age, sex and race \[in CHS only\]). Comparisons revealed significantly better predictive accuracy of the models with D~M~ for all outcomes in both studies: 0.674 versus 0.645 (*p* = .013) for mortality in FRAMCOHORT; 0.65 versus 0.642 (*p* = .017) for "robustness" in FRAMCOHORT; 0.719 versus 0.681 (*p* = .008) for "resilience" in FRAMCOHORT; 0.762 versus 0.741 (*p* \< .0001) for mortality in CHS; 0.576 versus 0.552 (*p* = .0002) for "robustness" in CHS; and 0.643 versus 0.583 (*p* \< .0001) for "resilience" in CHS. We note that such analyses, even though they indicated a significant improvement in predictive accuracy, are limited in scope as they do not take the dynamic characteristics of D~M~ into account and also are based on a limited number of biomarkers. More detailed analyses based on a larger panel of biomarkers in a different study will be reported elsewhere.

We also compared average age-trajectories of PD (represented by D~M~) for longer- versus shorter-lived study participants ([Figure 1](#F1){ref-type="fig"}). One can see from this figure that those individuals who survived to the oldest old age (ie, lifespan ≥ 90) may have a better (lower) initial level of PD, or slower increase of PD over the life course, or both. The figure also shows that the shorter- and longer-lived people may sometimes have similar initial levels of the dysregulation (see, eg, D~M~ trajectories for lifespan = 50--59 vs lifespan = 80--89 in Framingham males around the age 45) but different rates of their changes with age. This indicates the importance of considering both baseline D~M~ and its age-dynamics as predictors of longevity.

![Average age-trajectories of physiological dysregulation (represented by D~M~) for longer- vs shorter-lived study participants: (**A**) females in FRAMCOHORT; (**B**) females in CHS; (**C**) males in FRAMCOHORT; (**D**) males in CHS. Each trajectory presents average values (±*SE*) of D~M~ in 10-y age intervals for individuals dying at different ages shown in the legend ("50--59" to "80--89") or surviving until age 90 ("≥90").](gly13601){#F1}

[Table 2](#T2){ref-type="table"} summarizes the results of analyses of D~M~ in the Cox regression model. The results indicate that measures of PD (D~M~) constructed using data on biomarkers in two longitudinal studies (FRAMCOHORT and CHS) and two distinct reference populations (ages at baseline below 40 in FRAMCOHORT and 65--70 in CHS) show significant negative effect on onsets of "unhealthy life" (proxy for robustness), survival following onset of "unhealthy life" (proxy for resilience; however, it is only marginally significant in CHS), and total mortality in the Cox regression analyses. In FRAMCOHORT, hazard ratios (for a unit increase in D~M~) tend to be highest for robustness and lowest for resilience with mortality in between. In CHS, the hazard ratios for total mortality are the highest, followed by those for robustness and resilience. There was also a marked similarity between results obtained in FRAMCOHORT and CHS, specifically associations between PD and "robustness" were of much higher significance and effect size than the associations between PD and "resilience" ([Table 2](#T2){ref-type="table"}).

###### 

Results of Analyses of the Measure of Physiological Dysregulation (D~M~) in the Cox Regression Model in Applications to Mortality, Onset of "Unhealthy Life" (Considered as a Proxy for Robustness) and Survival Since Onset of "Unhealthy Life" (Considered as a Proxy for Resilience) in Framingham Heart Study Original Cohort (FRAMCOHORT) and Cardiovascular Heart Study (CHS)

  Study        Trait        Beta    *SE*    *p*-value   HR (95% CI)
  ------------ ------------ ------- ------- ----------- -------------------
  FRAMCOHORT   Mortality    0.209   0.022   7.2E-21     1.23 (1.18, 1.29)
               Robustness   0.297   0.017   6.3E-72     1.35 (1.3, 1.39)
               Resilience   0.136   0.03    7.6E-06     1.15 (1.08, 1.22)
  CHS          Mortality    0.404   0.05    8.1E-16     1.5 (1.36, 1.65)
               Robustness   0.277   0.036   2.0E-14     1.32 (1.23, 1.42)
               Resilience   0.212   0.099   3.2E-02     1.24 (1.02, 1.5)

*Note*: Beta is the estimate of respective regression coefficient in the Cox model (adjusted for sex in FRAMCOHORT, sex and race in CHS, plus age at onset of "unhealthy life" in case of "resilience" in both studies); results shown in the table are for D~M1~ (results for D~M2~ and D~M3~ are in [Supplementary Material](#sup1){ref-type="supplementary-material"}); HR is hazard ratio for a unit increase in D~M~ (95% confidence interval in brackets) which roughly corresponds to *SD* of D~M~ in the samples (1.15 and 0.87 in FRAMCOHORT and CHS, respectively).

These results indicate that simultaneous deviations of *multiple* physiological markers from their normal or baseline states may reflect a systemic (whole-body) level of vulnerability to a transition from healthy to diseased state (rather than the vulnerability to a particular disease), and to a lesser extent influence recovery from such diseased state.

The analyses by the Cox model provide general evidence that D~M~ is an important variable affecting robustness, resilience, and total mortality. Applications of SPM to these data allow investigation in more detail of how this measure can be related to hidden aging-related processes in an organism. [Table 3](#T3){ref-type="table"} presents results of analyses of D~M~ in SPM showing parameter estimates and the results of testing of different hypotheses (see Notes after the table for explanations of symbols, or the absence of those, used in different columns of the table, and [Supplementary Material](#sup1){ref-type="supplementary-material"} for description of parameters of the model).

###### 

Results of Analyses of the Measure of Physiological Dysregulation (D~M~) in the Stochastic Process Model (SPM) in Applications to Mortality, Onset of "Unhealthy Life" (Considered as a Proxy for Robustness) and Survival Since Onset of "Unhealthy Life" (Considered as a Proxy for Resilience) in Framingham Heart Study Original Cohort (FRAMCOHORT) and Cardiovascular Heart Study (CHS) (see footnotes \[a-c\] below)

  Study        Trait        ln *a*~*µ0*~   *b* ~*µ0*~   *b* ~*Sex*~   *b* ~*Race*~   *a* ~*Q*~   *b* ~*Q*~   *a* ~*Y*~   *b* ~*Y*~   σ~0~   σ~1~   *a* ~*f1*~   *b* ~*f1*~
  ------------ ------------ -------------- ------------ ------------- -------------- ----------- ----------- ----------- ----------- ------ ------ ------------ ------------
  FRAMCOHORT   Mortality    −11.05         0.105        1.99                         −1.76^†^    0.63^†^     −0.19       1.04^†^     0.95   0.58   2.12^†^      0.05^†^
               Robustness   −7.71          0.07         1.46                         −10.94^†^   3.91^†^     −0.2        1.17^†^     0.91   0.55   2.18^†^      0.04^†^
               Resilience   −6.9           0.048        1.13                         7.76^†^     −0.53       −0.18       0.6         1.22   1.39   2.44^†^      0.04^†^
  CHS          Mortality    −13.4          0.121        2.36          1.39           −4.92^†^    1.76\*      −0.27       0.002       0.91   0.58   1.41^†^      0.03^†^
               Robustness   −5.54          0.033        0.94          0.09           −1.67^†^    3.81        −0.28       0.03        0.9    0.56   1.43^†^      0.03^†^
               Resilience   −9.97          0.12         0.7           0.36           30.87\*     0.08        −0.29       0.03        0.9    1.03   1.91^†^      0.02^§^

*Notes*: (a) The estimates of some parameters are rescaled for better visibility in the table: $a_{Q}$ are multiplied by 10^4^; $b_{Q}$ are multiplied by 10^5^; $b_{Y}$are multiplied by 10^3^.

\(b\) The symbols after the numbers in the following columns of [Table 1](#T1){ref-type="table"} denote *p*-values (evaluated by the likelihood ratio test) for different null hypotheses:

Column "$a_{Q}$" : null hypothesis -- zero quadratic part of the hazard, ie, $Q(t) = 0$ ($a_{Q} = 0$ and $b_{Q} = 0$);

Column "$b_{Q}$" : null hypothesis -- age-independent J-shape of the hazard, ie, $Q(t) = a_{Q}(b_{Q} = 0)$;

Column "$b_{Y}$" : null hypothesis -- no aging-related decline in the adaptive capacity, ie, $a(t) = a_{Y}(b_{Y} = 0)$;

Column "$a_{f_{1}}$" : null hypothesis -- systemic dysregulation in an organism, ie, $f_{1}(t) = 0$ ($a_{f_{1}} = 0$ and $b_{f_{1}} = 0$

Column "$b_{f_{1}}$" : null hypothesis -- age-independent level of systemic physiological dysregulation, ie, $f_{1}(t) = a_{f_{1}}(b_{f_{1}} = 0)$

The symbols in these columns denote: ^†^*p* \< .0001; ^§^.0001 ≤ *p* \< .001; ^\#^.001 ≤ *p* \< .01; \*.01 ≤ *p* \< .05, for respective null hypotheses. The absence of symbols after the numbers in these columns means that respective *p*-values exceed .05. Note that all other columns in the table, except the columns mentioned above, are not used to represent information on testing any null hypotheses and therefore they do not contain any symbols.

\(c\) Results shown in the table are for D~M1~ (results for D~M2~ and D~M3~ are in [Supplementary Material](#sup1){ref-type="supplementary-material"}).

The table shows that the null hypotheses H0: $Q(t) = 0$ (see symbols in column "*a*~*Q*~") is rejected for all traits in both datasets (*p* \< .0001 for all cases except resilience in CHS where *p* = .04). This indicates that there is an additional quadratic term in the hazard rate ([equation S3](#sup1){ref-type="supplementary-material"} in [Supplementary Material](#sup1){ref-type="supplementary-material"}) so that respective traits are not entirely represented by the baseline Gompertz rate $\text{μ}_{0}(t)$ for all variants of D~M~. This confirms that D~M~ captures effects of deviations of physiological variables on respective traits in these two datasets so that non-zero values of D~M~ result in higher hazard rates for these outcomes compared to the baseline rates at a given age.

The null hypothesis H0: $Q(t) = a_{Q}$ (see symbols in column "*b*~*Q*~") is rejected for mortality and robustness in FRAMCOHORT (*p* \< .0001) and for mortality in CHS (*p* = .046). In these cases (taking into account that the parameter $b_{Q}$ is positive), we may conclude that the effect of PD (represented by D~M~) on respective risks is age-dependent and that the J-shape of the risk function (ie, as a function of D~M~ at any fixed age) narrows with age. This pattern indicates that the same level of PD (ie, the same value of D~M~) induces a larger increase in the risk at old ages than it does at younger ages (compared to the baseline hazard rate for respective age) so that the organism becomes more vulnerable to deviant dynamics of respective physiological variables in terms of total mortality and onset of "unhealthy life" ("robustness") (see also refs. ([@CIT0014]) and ([@CIT0022])). The results for the resilience trait and for robustness in CHS (ie, older reference population) were nonsignificant which means that in such cases there is not sufficient evidence that the J-shapes change with age.

The null hypotheses H0: $f_{1}(t) = 0$ (see symbols in column "*a*~*f1*~") and H0: $f_{1}(t) = a_{f_{1}}$(see symbols in column "*b*~*f1*~") are rejected in all cases (*p* \< .0001, except resilience in the latter case for CHS where *p* = .0003). Such deviations of D~M~ from zero with age indicate the presence of a systemic dysregulation in an organism that forces the trajectories of physiological variables to move away from their "normal values" (as specified in respective reference populations in calculation of D~M~). The effect of such dysregulation is that, on average, the values of physiological variables are different from the "normal" values minimizing respective risks so that the resulting hazard rates are higher than they could be in case of physiological variables at the "normal" level (ie, the baseline hazard rates corresponding to zero D~M~). The positive and significant values of $b_{f_{1}}$ indicate that the trajectories of D~M~ tend to deviate further from zero with age which results in an additional increase in the respective risks at older ages.

The null hypothesis H0: $a(t) = a_{Y}$(see symbols in column "*b*~*Y*~") is rejected (*p* \< .0001) for mortality and robustness in FRAMCOHORT. This means that respective feedback coefficient in [equation S2](#sup1){ref-type="supplementary-material"} (see [Supplementary Material](#sup1){ref-type="supplementary-material"}) becomes smaller (in absolute value) with age. This is interpreted as decline in adaptive capacity in an organism ([@CIT0014],[@CIT0022],[@CIT0027]) so that more time is needed for the trajectories of physiological variables to go back to their mean allostatic trajectories $f_{1}(t)$ at old ages compared to the time needed at younger ages. The results are not significant for the resilience trait in both datasets and for mortality and robustness in CHS. Thus, in this case there is not sufficient evidence to make such conclusion in relation to these traits (still, the estimates of $b_{Y} > 0$ in most cases). As discussed in ref. ([@CIT0015]), such mixed results can be partly explained by the inherent complexity of representation of the concept of adaptive capacity in SPM and this stimulates further developments of the methodological framework to address this topic.

Note that in the situation, in which the reference population represents much younger ages, the D~M~ may not necessarily reflect the level of PD, in a biological sense, but might instead be related to a change in the biological norm with age. Indeed, the "normal" values of a biomarker may be age-specific (see an example of BG in ref. ([@CIT0020])), so that the difference between values of such biomarker in an older versus younger age may potentially be due to the difference between normal age-values of that biomarker. This could be addressed by, for example, selecting the age-specific mean value (or the value corresponding to a lowest mortality risk in a given age) as the reference value, and analyze deviations from this value in the sample of the same age individuals. We are going to apply this alternative approach in our future analysis, and compare it with the current results.

Deviations of biomarkers' trajectories to higher and lower values may influence the studied outcomes differently which is not considered in the definition of D~M~. We note, however, that we use age interval at younger ages to define D~M~ before such effects can start producing noticeable differences ([@CIT0020]). In principle, SPM can accommodate non-symmetric U-shapes of the hazard rate and age-dependent "optimal ranges" ([@CIT0001]) to alleviate such situations. Also, for biomarkers that change non-monotonically with age, such as BMI, TC and HC, the D~M~ between the middle-aged and the oldest old individuals (eg, between 40 and 90 years old) may in principle be less than between the middle-aged and the old individuals (eg, between 40 and 65 years old). This does not mean that the level of PD in the body diminishes towards extreme ages, and people become physiologically more stable but may simply reflect the non-monotonic nature per se of the aging changes in such biomarkers. This could be addressed by selecting the age intervals, at which the biomarkers change monotonically, which generally happens at ages 70+ for the biomarkers used in this study (for examples of the age-trajectories of these biomarkers see ref. ([@CIT0028])).

We note also that the article reports on two types of analyses, the Cox model and SPM. The former does not model the dynamics of the longitudinal variables whereas the latter does using the stochastic differential equation. The actual relationship between the longitudinal variables and time-to-event outcomes can be even more complicated and involve time lag effects, cumulative effects (ie, integrals), rate of change (ie, derivatives), etc. Such effects can be analyzed using, for example, the joint models ([@CIT0029],[@CIT0030]), or extensions of SPM which are left for future work.

It is also important to stress that D~M~ based on multiple biomarkers (which is the focus of this article), as compared to values of individual biomarkers, or D~M~ values based on a single biomarker---represent conceptually different components of the vulnerability to death, which is a highly heterogeneous trait. That is, D~M~ based on deviations of multiple biomarkers from their baseline states characterizes level of *systemic dysregulation* in the body, which does not specifically require a biomarker to be abnormal or take value typical of a pathological state. For the D~M~ based on multiple biomarkers, each deviation from baseline may in principle lie within a clinically normal range, so that quantity and variety of biomarkers play more of a role in this estimate than manifestation of any individual marker in regard to a particular pathology. Predictive effects of the composite D~M~, and the D~M~ based on individual biomarkers, should not, therefore, be directly compared since they represent different contributors to the heterogeneity of longevity (ie, systemic dysregulation that increases overall vulnerability vs specific metabolic change that increases risk of particular disease). Due to its systemic nature, the D~M~ based on multiple biomarkers is conceptually closer to the idea of "deficits indices" that represent overall burden of physiological and health problems in the body, no matter how small each problem might be, which together may influence the overall vulnerability to disease and death, see, for example, refs. ([@CIT0031],[@CIT0032]).

Concluding Remarks {#s7}
==================

We found that the level of PD increases with aging in both males and females. Measures of PD (D~M~) constructed using data on biomarkers in two longitudinal human studies (FRAMCOHORT and CHS) show significant negative effects on transition from healthy to unhealthy state (proxy for robustness), and to a lesser extent on survival following the onset of unhealthy life (proxy for resilience), and on total mortality in the Cox regression analyses. Analyses of D~M~ using SPM confirmed its significant effect on mortality, robustness, and resilience and revealed significant relationships with other aging-related characteristics.

This implies that robustness and resilience may have overlapping as well as distinct biological mechanisms, which warrants exploration of genetic background of the PD and its relevance to longevity and disease-related pathways, in subsequent analysis.

Our results also support a potentially important application of PD, or its equivalent, in clinical settings that regularly collect information about repeated measures of patients' blood tests and results of physical exams over the years (which refers to most primary care facilities in the United States). Currently, health care professionals pay more attention to values of individual biomarkers that correspond to clinical or preclinical manifestations of particular disease (eg, a fasting blood glucose level over 125 mg/dL indicates diabetes, and the range of 110 to 125 mg/dL indicates prediabetes). A more sophisticated approach includes using a cluster of *abnormal* values of the different biomarkers that occur together, to predict disease risk. Metabolic syndrome could be an example, in which a combination of abnormally increased blood pressure, blood sugar, body fat around the waist and cholesterol and triglyceride levels, is treated as a composite risk factor for heart disease, stroke, and diabetes. The use of PD measures represents an additional step forward because it allows to utilize not only clinically "abnormal" values of biomarkers, but also those deviations from the baseline physiological state, which "individually" would not be considered strong risk factors for disease, but together may significantly contribute to the transition from healthy to unhealthy state.

Our results suggest that such "multiple" deviations of biomarkers from their baseline physiological states (reflected in higher PD levels) may precede clinical manifestation of not just one but many diseases, even if some deviations are small and not clearly abnormal for individual markers. The main informative value of PD for clinicians could, therefore, be in "quantity" rather than in quality of the biomarker deviations. The multiple deviations of biomarkers may signal that regulatory mechanisms are broadly compromised across tissues and systems of the body, which could make a person more susceptible to a variety of diseases (with specific manifestations dependent on individual genetic predisposition and history of exposures). Thus, measures of PD might be used by the primary care physicians as new preclinical indicators of a person's transition from a healthy to an unhealthy state even in the absence of strong clinical diagnostic markers pointing out to specific pathology.

Funding {#s9}
=======

This work was supported by the National Institutes of Health (grant numbers R01AG046860, P01AG043352, P30AG034424, and 5P30 AG028716-11). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Supplementary Material
======================

###### 

Click here for additional data file.

This manuscript was prepared using CHS and FRAMCOHORT Research Materials obtained from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of the CHS, FRAMCOHORT or the NHLBI. Alan A. Cohen is supported by a CIHR New Investigator Salary Award and is a member of the *Fonds de recherche du Québec -- Santé funded Centre de recherche du CHUS and Centre de recherche sur le vieillissement*.

Conflict of Interest {#s10}
====================

None declared.
